Shared Care Agreement Insulin Degludec (Tresiba )
|
|
- Brenda Walton
- 8 years ago
- Views:
Transcription
1 Licensed Indication Shared Care Agreement Insulin Degludec (Tresiba ) Insulin Degludec is licensed for the treatment of diabetes mellitus in adults. Countess of Chester prescribing guidelines Restricting the use of insulin degludec to patients who have: 1. Type 1 diabetes with recurrent severe hypoglycaemia, who have trialled available long acting analogues but are unable to achieve target HbA1c and/or nocturnal hypoglycaemia remains a problem before starting insulin pump therapy. 2. Type 1 diabetes with recurrent severe hypoglycaemia, who have trialled available long acting analogues but are unable to achieve target HbA1c and/or nocturnal hypoglycaemia remains a problem and are unsuitable for insulin pump therapy (i.e., visually impaired, not motivated to dose adjust based on carbohydrate counting). 3. Type 2 diabetes, who are insulin resistant, with poor control on greater than 200units of insulin per day. These patients will use 200units/ml pen as this will allow large doses to be given in a smaller volume resulting in better absorption and therefore better control of blood glucose. Dose and administration Insulin degludec should be administered once daily at any time of the day, with a minimum interval of 8 hours between doses, but preferably at the same time each day. Insulin degludec is to be dosed in accordance with the individual patient s needs. Dose adjustment should be based on fasting plasma glucose to optimise glycaemic control. In type 1 diabetes it must be combined with short/rapid-acting insulin to cover meal-time requirements. In type 2 diabetes the starting dose is 10 units per day. When adding insulin degludec to GLP-1 receptor agonists, the recommended daily starting dose is 10 units followed by individual dosage adjustments. When adding GLP-1 receptor agonists to insulin degludec, it is recommended to reduce the dose of insulin degludec by 20% to minimise the risk of hypoglycaemia. Subsequently, dosage should be adjusted individually. Note: One unit of insulin degludec corresponds to one unit of human insulin, one unit of insulin glargine or one unit of insulin detemir. Insulin Degludec (Tresiba ) shared care FINAL v1.0 Uploaded by Liz Kowlessar, December 2014
2 Adverse effects The most frequently reported adverse reaction during treatment is hypoglycaemia. Immune system disorders With insulin preparations, allergic reactions may occur. Immediate-type allergic reactions to either insulin itself or the excipients may potentially be life-threatening. Hypersensitivity (manifested with swelling of tongue and lips, diarrhoea, nausea, tiredness and itching) and urticaria reactions were reported rarely in clinical trial data. Hypoglycaemia Hypoglycaemia may occur if the insulin dose is too high in relation to the insulin requirement. Severe hypoglycaemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or even death. The symptoms of hypoglycaemia usually occur suddenly. They may include cold sweats, cool pale skin, fatigue, nervousness or tremor, anxiousness, unusual tiredness or weakness, confusion, difficulty in concentration, drowsiness, excessive hunger, vision changes, headache, nausea and palpitation. Lipodystrophy Lipodystrophy (including lipohypertrophy, lipoatrophy) may occur at the injection site. Continuous rotation of the injection site within the particular injection area may help to reduce the risk of developing these reactions. Injection site reactions Injection site reactions (including injection site haematoma, pain, haemorrhage, erythema, nodules, swelling, discolouration, pruritus, warmth and injection site mass) occurred in patients treated with Tresiba. These reactions are usually mild and transitory and they normally disappear during continued treatment. As insulin degludec is a new drug all adverse reactions should be reported to MHRA. Contraindications and warnings Hypersensitivity to the active substance or to any of the excipients listed. Tresiba should not be used during pregnancy, breast-feeding and for children under the age of eighteen as there is no experience of use in this group. Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac failure. This should be kept in mind if treatment with the combination of pioglitazone and Tresiba is considered. Tresiba must not be administered intravenously as it may result in severe hypoglycaemia. Tresiba must not be administered intramuscularly as it may change the absorption. Tresiba must not be used in insulin infusion pumps. Insulin Degludec (Tresiba ) shared care FINAL v1.0 Uploaded by Liz Kowlessar, December 2014
3 Drug Interactions The following substances may reduce the insulin requirement Oral anti diabetic medicinal products, GLP-1 receptor agonists, monoamine oxidase inhibitors (MAOI), beta-blockers, angiotensin converting enzyme (ACE) inhibitors, salicylates, anabolic steroids and sulphonamides. The following substances may increase the insulin requirement Oral contraceptives, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth hormone and danazol. Beta-blockers may mask the symptoms of hypoglycaemia. Octreotide/lanreotide may either increase or decrease the insulin requirement. Alcohol may intensify or reduce the hypoglycaemic effect of insulin Monitoring requirements In accordance with NICE guidance, patients must be monitored to ensure metabolic response of reduction in HbA1c. Refer back or discuss with secondary care if not achieved. Routine capillary blood glucose monitoring must be undertaken as with any other basal insulin therapy. Preparations available FlexTouch 100 units/ml 3ml prefilled pen provides accurate dosing up to 80 units of insulin (from 1-80 units in 1 unit increments) FlexTouch 200 units/ml 3ml prefilled pen which provides accurate dosing up to 160 units of insulin (from units in 2 unit increments) The dose counter shows the number of units regardless of strength and no dose conversion should be done when transferring a patient to a new strength. Penfill 100 units/ml cartridges 3ml compatible with Novo Nordisk durable delivery devices (such as NovoPen 4). Insulin Degludec (Tresiba ) shared care FINAL v1.0 Uploaded by Liz Kowlessar, December 2014
4 Before first use: Store in a refrigerator (2 8 C). Keep away from the freezing element. Do not freeze. After first opening or carried as a spare: After first opening, the product may be stored for a maximum of 8 weeks. Do not refrigerate. Do not store above 30 C. Keep cartridges in the outer carton in order to protect from light. Cost For one year treatment (excluding VAT) based on 52 units daily 911 per patient per year. RESPONSIBILITIES Specialist responsibilities (consultant only) 1. Identify patients who may benefit from insulin degludec treatment as per COCH guidelines. 2. Discuss the benefits and side effects of treatment with the patient to enable them to make informed choices about how to manage their diabetes. 3. Initiate treatment and assess response for at least three months. Treatment should only be continued beyond this time period, and in the longer term, if there is a demonstrable improvement in the frequency and severity of hypoglycaemia whilst maintaining HbA1c that is judged to be clinically relevant to the individual patient s overall risk of developing long term complications of diabetes and hospitalisation due to hypoglycaemia. 4. Stabilise patient on insulin degludec before asking the GP to commence prescribing. 5. Report all adverse events to the MHRA. GP responsibilities 1. To prescribe insulin degludec as recommended by the specialist at COCH. 2. If unwilling to continue prescribing insulin degludec, please complete the attached form (Appendix 1), stating reasons and return to the consultant as soon as possible. 3. If patient develops worsening blood glucose control then to inform the specialist. 4. To report all adverse events to the specialist and the MHRA. Additional information This document should be read in conjunction with the Summary of Product Characteristics (SPC). The doctor who prescribes the medication assumes legal responsibility for the drug. Contacts Dr David Ewins Consultant Endocrinologist, COCH Dr Frank Joseph Consultant Endocrinologist, COCH Dr Sunil Nair Consultant Endocrinologist, COCH Sister Karen Perkins, Diabetes Specialist Nurse, COCH Haley Toop, Endocrinology Pharmacist, COCH References: 1. Summary of Product Characteristics. Insulin Degludec (Tresiba ) Novo nordisk. Accessed June Insulin Degludec (Tresiba ) shared care FINAL v1.0 Uploaded by Liz Kowlessar, December 2014
5 Appendix 1: Shared Care Agreement Insulin degludec To be completed by GP if not in agreement with continued prescribing Name of patient Date of Birth Address Patient NHS No I do not agree to prescribe insulin degludec for the above patient in accordance with the enclosed shared care protocol. Reason for not wanting to continue prescription GP Date Insulin Degludec (Tresiba ) shared care FINAL v1.0 Uploaded by Liz Kowlessar, December 2014
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationPackage Leaflet: Information for the user
Package Leaflet: Information for the user Actrapid 100 IU/ml solution for injection in vial Insulin human (rdna) Read all of this leaflet carefully before you start using your insulin Keep this leaflet.
More informationNew Zealand Consumer Medicine Information
New Zealand Consumer Medicine Information Actrapid Penfill 100 IU/ml solution for injection in cartridge Insulin human (rdna) Read all of this leaflet carefully before you start using your insulin Keep
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS . NAME OF THE MEDICINAL PRODUCT Insulatard 40 international units/ml suspension for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION vial contains 0 ml
More informationNew Zealand Datasheet
Name of Medicine ACTRAPID Neutral insulin 100 IU/ml New Zealand Datasheet Presentation ACTRAPID is a clear colourless solution containing 100% neutral human insulin. It is available in 3 ml Penfill cartridges
More informationNew Zealand Consumer Medicine Information
New Zealand Consumer Medicine Information PenMix 30 100 IU/ml suspension for injection in cartridge PenMix 40 100 IU/ml suspension for injection in cartridge PenMix 50 100 IU/ml suspension for injection
More informationDo not use Tresiba if you are allergic to insulin degludec or any of the other ingredients of this medicine (listed in section 6).
Front Page: 1 Package leaflet: Information for the patient Tresiba 200 units/ml Solution for injection in pre-filled pen insulin degludec This medicine is subject to additional monitoring. This will allow
More informationNew Zealand Datasheet
New Zealand Datasheet Name of Medicine PENMIX 30 Biphasic isophane insulin injection 100 IU/ml PENMIX 40 Biphasic isophane insulin injection 100 IU/ml PENMIX 50 Biphasic isophane insulin injection 100
More informationNovoRapid is a modern insulin (insulin analogue) with a rapid acting effect. Modern insulin products are improved versions of human insulin.
Package leaflet: Information for the user NovoRapid FlexTouch 100 units/ml Solution for injection in pre filled pen Insulin aspart Read all of this leaflet carefully before you start using this medicine
More informationPackage leaflet: Information for the user. Insulatard 100 international units/ml suspension for injection in vial human insulin
Package leaflet: Information for the user Insulatard 100 international units/ml suspension for injection in vial human insulin Read all of this leaflet carefully before you start using this medicine because
More informationפורמט עלון זה נקבע ע"י משרד הבריאות ותוכנו נבדק ואושר במאי 4102
פורמט עלון זה נקבע ע"י משרד הבריאות ותוכנו נבדק ואושר במאי 4102 1. NAME OF THE MEDICINAL PRODUCT Insulatard Penfill 100 iu/ml suspension for injection in cartridge. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationInsulin human, rdna (produced by recombinant DNA technology in Saccharomyces cerevisiae).
Prescribing Information 1. NAME OF THE MEDICINAL PRODUCT INSULATARD vial 100 IU/ml Suspension for injection in a vial INSULATARD Penfill 100 IU/ml Suspension for injection in a cartridge 2. QUALITATIVE
More informationA direction leaflet containing information for the patient is included in each package.
Novolin ge Penfill Premixed insulin preparations Insulin Injection 30% and Insulin Isophane 70% Insulin Injection 40% and Insulin Isophane 60% Insulin Injection 50% and Insulin Isophane 50% Human Biosynthetic
More informationHUMULIN R REGULAR INSULIN HUMAN INJECTION, USP (rdna ORIGIN) 100 UNITS PER ML (U-100)
1 PATIENT INFORMATION HUMULIN R REGULAR INSULIN HUMAN INJECTION, USP (rdna ORIGIN) 100 UNITS PER ML (U-100) WARNINGS Do not share your syringes with other people, even if the needle has been changed. You
More informationImportant: Please Read PART III: CONSUMER INFORMATION
GlucoNorm 0.5 mg, 1 mg and 2 mg Repaglinide Tablets Oral anti-diabetic agent Important: Please Read PART III: CONSUMER INFORMATION Read this carefully before you start taking GlucoNorm and each time you
More informationPART III: CONSUMER INFORMATION. Important: Please Read
PART III: CONSUMER INFORMATION NovoRapid [vial/penfill / FlexPen /FlexTouch ] Important: Please Read Insulin Aspart Solution for Injection 10 ml / 3 ml This leaflet is Part III of a three-part Product
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Novolin ge Toronto Insulin Injection Human Biosynthetic Penfill /vial Read this carefully before you start taking Novolin
More informationPackage leaflet: Information for the user Humalog 200 units/ml, solution for injection in pre-filled pen insulin lispro
Package leaflet: Information for the user Humalog 200 units/ml, solution for injection in pre-filled pen insulin lispro Read all of this leaflet carefully before you start using this medicine because it
More informationNovoRapid is a modern insulin (insulin analogue) with a rapid acting effect. Modern insulin products are improved versions of human insulin.
Package leaflet: Information for the user NovoRapid FlexPen 100 units/ml Solution for injection in pre filled pen Insulin aspart Read all of this leaflet carefully before you start using this medicine
More informationPRODUCT INFORMATION. Human insulin (rys) is characterised by being identical to natural human insulin.
Inshpi12a.docx Page 1 of 10 PRODUCT INFORMATION NAME OF THE MEDICINE Human insulin (rys) DESCRIPTION Human insulin (rys) is characterised by being identical to natural human insulin. CAS No: 11061-68-0
More informationSummary of the risk management plan (RMP) for Xultophy (insulin degludec / liraglutide)
EMA/467911/2014 Summary of the risk management plan (RMP) for Xultophy (insulin degludec / liraglutide) This is a summary of the risk management plan (RMP) for Xultophy, which details the measures to be
More informationHumulin (HU-mu-lin) R
1 PATIENT INFORMATION Humulin (HU-mu-lin) R Regular U-500 (Concentrated) insulin human injection, USP (rdna origin) Read the Patient Information that comes with Humulin R U-500 before you start taking
More informationNovoMix 30 Penfill 100 units/ml suspension for injection in a cartridge 30% soluble insulin aspart and 70% insulin aspart crystallised with protamine
Package leaflet: Information for the user NovoMix 30 Penfill 100 units/ml suspension for injection in a cartridge 30% soluble insulin aspart and 70% insulin aspart crystallised with protamine Read all
More informationIMPORTANT: PLEASE READ
PART III: CONSUMER INFORMATION HUMULIN R CARTRIDGES insulin injection, human biosynthetic (rdna origin) Solution for Injection, 100 units/ml and HUMULIN R KWIKPEN insulin injection, human biosynthetic
More informationN HUMAN Novo Nordisk Patient Information for Novolin N
N HUMAN Novo Nordisk Patient Information for Novolin N NOVOLIN N (NO-voe-lin) NPH, Human Insulin Isophane Suspension Injection (recombinant DNA origin) 100 units/ml Important: Know your insulin. Do not
More informationSafe use of insulin e- learning module
Safe use of insulin e- learning module Page 1 Introduction Insulin is a hormone produced by the beta cells in the pancreas, it is released when blood glucose levels are raised for example after a meal.
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Humalog 100 U/ml, solution for injection in vial 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 2.1 General description Humalog
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER
PACKAGE LEAFLET: INFORMATION FOR THE USER Humalog Mix50 100 U/ml KwikPen, suspension for injection insulin lispro Read all of this leaflet carefully before you start using this medicine because it contains
More informationThe monthly newsletter from the MHRA and its independent advisor the Commission on Human Medicines
Latest advice for medicines users The monthly newsletter from the MHRA and its independent advisor the Commission on Human Medicines Volume 6, Issue 9, April 2013 Drug safety advice Hot topic Stop press
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user NovoMix 30 FlexPen 100 units/ml suspension for injection in a pre-filled pen 30% soluble insulin aspart and 70% insulin aspart crystallised with protamine Read
More informationInsulin Pump Therapy for Type 1 Diabetes
Insulin Pump Therapy for Type 1 Diabetes Aim(s) and objective(s) This guideline has been developed to describe which patients with Type 1 Diabetes should be referred for assessment for insulin pump therapy
More informationHumulin R (U500) insulin: Prescribing Guidance
Leeds Humulin R (U500) insulin: Prescribing Guidance Amber Drug Level 2 We have started your patient on Humulin R (U500) insulin for the treatment of diabetic patients with marked insulin resistance requiring
More information1 2 INFORMATION FOR THE PATIENT 3 10 ml Vial (1000 Units per vial)
1 1 2 INFORMATION FOR THE PATIENT 3 10 ml Vial (1000 Units per vial) 4 HUMULIN N 5 NPH 6 HUMAN INSULIN (rdna ORIGIN) 7 ISOPHANE SUSPENSION 8 100 UNITS PER ML (U-100) 9 WARNINGS 10 THIS LILLY HUMAN INSULIN
More informationProtaphane InnoLet Mixtard 30/70 InnoLet
Protaphane InnoLet Mixtard 30/70 InnoLet Human insulin (rys) Consumer Medicine Information What is in this leaflet What human insulin is used for 1 Before you use human insulin InnoLet...1 How to use human
More informationisophane human insulin (prb) A Guide to Starting Humulin I
isophane human insulin (prb) A Guide to Starting Humulin I This leaflet is intended only for those individuals who have been prescribed Humulin I. It is intended to be used in addition to the Patient Information
More informationMedicines Management
Medicines Management Patient Group Direction for the Supply/administration of Adrenaline (Epinephrine) for Treatment of Anaphylaxis by accredited community Pharmacists. Rationale To enable a pharmacist,
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. ADRENALINE (TARTRATE) STEROP 1 mg/1 ml Solution for injection. Adrenaline (Levorenine, Epinephrine)
PACKAGE LEAFLET: INFORMATION FOR THE USER ADRENALINE (TARTRATE) STEROP 1 mg/1 ml Solution for injection Adrenaline (Levorenine, Epinephrine) Read all of this leaflet carefully before you start using this
More informationDonepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa )
Donepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa ) ESCA: For the treatment of Alzheimer s disease. SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR
More informationThioctacid 600 T Solution for Injection contains 600 mg alpha-lipoic acid
Package Leaflet: Information for the User Thioctacid 600 T Solution for Injection contains 600 mg alpha-lipoic acid For use in adults Active substance: Alpha-lipoic acid, Trometamol salt (1:1) Read all
More information2. What Should Advocates Know About Diabetes? O
2. What Should Advocates Know About Diabetes? O ften a school district s failure to properly address the needs of a student with diabetes is due not to bad faith, but to ignorance or a lack of accurate
More informationCochrane Quality and Productivity topics
Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus NICE has developed the Cochrane Quality and Productivity (QP) topics to help the NHS identify practices
More informationP A T I E N T I N F O R M A T I O N. Apidra
P A T I E N T I N F O R M A T I O N Apidra We have written this leaflet for those of you with diabetes who have been prescribed Apidra by your doctor. The primary goal of all diabetes treatment is to achieve
More informationA Guide to Monitoring Blood Glucose for Patients with diabetes in Care Homes
A Guide to Monitoring Blood Glucose for Patients with diabetes in Care Homes 1. Summary... 1 2. Background... 2 3. Purpose 2 4. Responsibilities. 2 5. Blood Glucose Monitoring. 2 6. Resident Groups that
More informationHUMULIN R REGULAR INSULIN HUMAN INJECTION, USP (rdna ORIGIN) 100 UNITS PER ML (U-100)
1 INFORMATION FOR THE PATIENT 10 ml Vial (1000 Units per vial) A1.0 NL 5691 AMP A1.0 NL 5681 AMP A2.0 NL 4460 AMP HUMULIN R REGULAR INSULIN HUMAN INJECTION, USP (rdna ORIGIN) 100 UNITS PER ML (U-100) WARNINGS
More informationAre insulin analogs worth their cost in type 2 diabetes?
Keystone, Colorado 2012 Are insulin analogs worth their cost in type 2 diabetes? Dr. Amanda Adler Consultant Physician, Institute of Metabolic Sciences Addenbrooke s Hospital, Cambridge Chair, Technology
More informationPRODUCT INFORMATION HUMULIN
PRODUCT INFORMATION HUMULIN NAME OF DRUG HUMULIN R (Regular Neutral Soluble Human Insulin (rbe) Injection) HUMULIN NPH (Isophane NPH Human Insulin (rbe) Suspension) HUMULIN 30/70 (30% Regular Human Insulin
More informationNew Zealand Consumer Medicine Information. 30% soluble insulin aspart (rys) and 70% insulin aspart (rys) crystallised with protamine
New Zealand Consumer Medicine Information NovoMix 30 FlexPen 30% soluble insulin aspart (rys) and 70% insulin aspart (rys) crystallised with protamine What is in this leaflet This leaflet answers some
More information1 What Anapen is and what it is used for?
PACKAGE LEAFLET: INFORMATION FOR THE USER Anapen 500 micrograms in 0.3 ml solution for injection (pre-filled syringe) Adrenaline (Epinephrine) Auto-Injector Read all of this leaflet carefully before you
More informationInsulin Safety. The safe use of insulin and you. Patient Information Booklet
Insulin Safety The safe use of insulin and you The Right insulin The Right dose The Right way The Right time Hypoglycaemia Diabetes Patient Information Booklet Adapted from the National Patient Safety
More informationHUMALOG MIX 25 & HUMALOG MIX 50 KwikPen
The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in September 2011. HUMALOG MIX 25 & HUMALOG MIX 50 KwikPen 1. NAME OF THE MEDICINAL PRODUCT
More informationInstruction of 30/70 mixture Recombinant Human Insulin Injection
Instruction of 30/70 mixture Recombinant Human Insulin Injection Name: Generic Name: 30/70 mixture Recombinant Human Insulin Injection Commercial Name: Gansulin 30R (Dongbao Cartridge) English Name: 30/70
More informationINFORMATION FOR THE PATIENT. 3 ML DISPOSABLE INSULIN DELIVERY DEVICE HUMULIN N Pen NPH HUMAN INSULIN (rdna ORIGIN) ISOPHANE SUSPENSION
1 PA 9132 FSAMP INFORMATION FOR THE PATIENT 3 ML DISPOSABLE INSULIN DELIVERY DEVICE HUMULIN N Pen NPH HUMAN INSULIN (rdna ORIGIN) ISOPHANE SUSPENSION WARNINGS THIS LILLY HUMAN INSULIN PRODUCT DIFFERS FROM
More informationSHORT CLINICAL GUIDELINE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2
More informationA list of all medications you are taking also include any vitamins, supplements, over-the-counter medicines, or herbal products
This is your customized insulin discussion guide to bring to your next doctor s visit. WHAT TO BRING TO YOUR NEXT CHECK UP A record of your recent blood sugar readings A list of all medications you are
More informationPackage leaflet : information for the user. Dilute Adrenaline/Epinephrine Injection 1:10,000 adrenaline (epinephrine) (as acid tartrate) 0.
Package leaflet : information for the user Dilute Adrenaline/Epinephrine Injection 1:10,000 adrenaline (epinephrine) (as acid tartrate) 0.1mg per ml Because of your condition it may not be possible for
More informationLead Clinician(S) (DATE) Approved by Diabetes Directorate on: Approved by Medicines Safety Group on: This guideline should not be used after end of:
Guideline for members of the diabetes team and dietetic department for advising on insulin dose adjustment and teaching the skills of insulin dose adjustment to adults with type 1 or type 2 diabetes mellitus
More informationPart B: 3 3. DIABETES MELLITUS. 3.1.1 Effects of diabetes on driving. 3.1.2 Evidence of crash risk. 3.2.1 Hypoglycaemia
3. DIABETES MELLITUS Refer also to section 6 Neurological conditions, section 2 Cardiovascular conditions, section 8 Sleep disorders section 10 Vision eye disorders. 3.1 Relevance to the driving task 3.1.1
More informationOxford University Hospitals. NHS Trust. Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis. Information for patients
Oxford University Hospitals NHS Trust Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis Information for patients page 2 What is Natalizumab and what is it used for? Natalizumab is an
More informationUBISTESIN 1:200,000 and UBISTESIN FORTE 1:100,000
UBISTESIN 1:200,000 and UBISTESIN FORTE 1:100,000 Articaine hydrochloride and adrenaline hydrochloride Consumer Medicine Information WHAT IS IN THIS LEAFLET Please read this leaflet carefully before you
More informationAdjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.
Shared Care Guideline for Prescription and monitoring of Naltrexone Hydrochloride in alcohol dependence Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist,
More informationEfficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics
Efficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics This trial is conducted in the United States of America (USA). The aim of this clinical
More informationA Guide to Starting. Humalog Mix25
A Guide to Starting Humalog Mix25 This booklet is intended only for those individuals who have been prescribed Humalog Mix 25. It is intended to be used in addition to the Patient Information Leaflet (PIL)
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. ADRENALINE (HCl) STEROP 0,8mg/1ml. Solution for injection. Adrenaline (Levorenine, Epinephrine)
PACKAGE LEAFLET: INFORMATION FOR THE USER ADRENALINE (HCl) STEROP 0,4mg/1ml ADRENALINE (HCl) STEROP 0,8mg/1ml Solution for injection Adrenaline (Levorenine, Epinephrine) Read all of this leaflet carefully
More informationYOUR GUIDE TO THE LANTUS SOLOSTAR INSULIN PEN
Important Safety Information for Lantus You must test your blood sugar levels while using insulin, such as Lantus. Do not make any changes to your dose or type of insulin without talking to your healthcare
More informationInsulin pens workshop Making the complex simple
Agenda: Insulin doses Needles Insulin Pen Devices Insulin storage Key information (Patient &HCP) Injection sites Hypoglycaemia Home blood glucose testing Sick day advice Traveling Sharps Insulin pens workshop
More informationhuman insulin (prb) 30% soluble insulin 70% isophane insulin A Guide to Starting Humulin M3
human insulin (prb) 30% soluble insulin 70% isophane insulin A Guide to Starting Humulin M3 This booklet is intended only for those who have been Prescribed Humulin M3. It is intended to be used in addition
More informationUser guide Basal-bolus Insulin Dosing Chart: Adult
Contacts and further information Local contact Clinical pharmacy or visiting pharmacy Diabetes education service Director of Medical Services Visiting or local endocrinologist or diabetes physician For
More informationClinical Performance Director of Nursing Allison Bussey
PGD 0314 Patient Group Direction Administration of Adrenaline (Epinephrine) 1:1000 (1mg/ml) Injection By Registered Nurses employed by South Staffordshire & Shropshire Healthcare Foundation NHS Trust This
More informationMaintenance of abstinence in alcohol dependence
Shared Care Guideline for Prescription and monitoring of Acamprosate Calcium Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist, Alcohol Services Dr Donnelly
More informationA1.08 NL 3053 AMP INFORMATION FOR THE PHYSICIAN
1 A1.08 NL 3053 AMP INFORMATION FOR THE PHYSICIAN HUMULIN R REGULAR U-500 (CONCENTRATED) INSULIN HUMAN INJECTION, USP (rdna ORIGIN) DESCRIPTION Humulin R U-500 is a polypeptide hormone structurally identical
More informationGESTATIONAL DIABETES (DIET/INSULIN/METFORMIN) CARE OF WOMEN IN BIRTHING SUITE
GESTATIONAL DIABETES (DIET/INSULIN/METFORMIN) CARE OF WOMEN IN BIRTHING SUITE DEFINITION A disorder characterised by hyperglycaemia first recognised during pregnancy due to increased insulin resistance
More informationGuideline for Insulin Therapeutic Review in patients with Type 2 Diabetes
Diabetes Sans Frontières Guideline for Insulin Therapeutic Review in patients with Type 2 Diabetes 1. Introduction This guideline has been developed in order to support practices to undertake insulin therapeutic
More informationHarmony Clinical Trial Medical Media Factsheet
Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual
More informationTdaP-Booster (tee-dee-ay-pee boo-ster)
New Zealand Consumer Medicine Information TdaP-Booster (tee-dee-ay-pee boo-ster) Tetanus, diphtheria and pertussis (acellular mono-component) vaccine (adsorbed, reduced antigen content) CONSUMER MEDICINE
More informationContinuous Subcutaneous Insulin Infusion (CSII) pump therapy
Continuous Subcutaneous Insulin Infusion (CSII) pump therapy GHPI1267_04_15 Department: Diabetes team Review due: April 2018 www.gloshospitals.nhs.uk 21 BETTER FOR YOU BETTER FOR YOU 1 Introduction This
More informationX-Plain Diabetes - Introduction Reference Summary
X-Plain Diabetes - Introduction Reference Summary Introduction Diabetes is a disease that affects millions of Americans every year. Your doctor may have informed you that you have diabetes. Although there
More informationOptiSet delivers insulin in increments of 2 IU up to a maximum single dose of 40 IU.
1. NAME OF THE MEDICINAL PRODUCT Insuman Rapid 100 IU/ml solution for injection in a cartridge Insuman Rapid 100 IU/ml solution for injection in a pre-filled pen. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationINSULINThere are. T y p e 1 T y p e 2. many different insulins for
T y p e 1 T y p e 2 INSULINThere are many different insulins for Characteristics The three characteristics of insulin are: Onset. The length of time before insulin reaches the bloodstream and begins lowering
More informationMedication Guide. SYMLIN (SĬM-lĭn) (pramlintide acetate) injection
Page 1 Medication Guide SYMLIN (SĬM-lĭn) (pramlintide acetate) injection Read the Medication Guide and the Patient Instructions for Use that come with your SYMLIN product before you start using it and
More informationInsulin Pump Therapy during Pregnancy and Birth
Approvals: Specialist Group: Miss F Ashworth, Dr I Gallen, Dr J Ahmed Maternity Guidelines Group: V1 Dec 2012 Directorate Board: V1 Jan 2013 Clinical Guidelines Subgroup: July 2011 MSLC: V1 Nov 2012 Equality
More informationGMMMG Interface Prescribing Subgroup. Shared Care Template
GMMMG Interface Prescribing Subgroup Shared Care Template Shared Care Guideline for Selective Serotonin Reuptake Inhibitors (SSRIs) for the treatment of Obsessive Compulsive Disorder (OCD) and Body Dysmorphic
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Apidra 100 Units/ml solution for injection in a vial 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 100 Units
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Lantus 100 units/ml solution for injection in a vial 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 100 units
More informationEpipen Junior 150 micrograms solution for injection in pre-filled pen
Package leaflet: Information for the user Epipen Junior 150 micrograms solution for injection in pre-filled pen Read all of this leaflet carefully before you start using this medicine because it contains
More informationAnaphylaxis: Treatment in the Community
: Treatment in the Community is likely if a patient who, within minutes of exposure to a trigger (allergen), develops a sudden illness with rapidly progressing skin changes and life-threatening airway
More informationStowe School Medications Policy
INTRODUCTION Most pupils will need medication at some stage of their school life. Although this will mainly be for short periods there are a few pupils with chronic conditions who may require regular medication
More informationTeriflunomide (Aubagio) 14mg once daily tablet
Teriflunomide (Aubagio) 14mg once daily tablet Exceptional healthcare, personally delivered Your Consultant Neurologist has suggested that you may benefit from treatment with Teriflunomide. The decision
More information-------------------------------CONTRAINDICATIONS----------------------------- Do not use during episodes of hypoglycemia. (4)
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HUMULIN R U-500 safely and effectively. See full prescribing information for HUMULIN R U-500. HUMULIN
More informationGilenya. Exceptional healthcare, personally delivered
Gilenya Exceptional healthcare, personally delivered Your Consultant Neurologist has suggested that you may benefit from treatment with Gilenya. The decision to start this form of treatment can be difficult.
More informationP AC K AG E L E AF L E T: INFORMAT I ON FO R THE USER. 500 mg, film-coated tablet Active substance: metformin hydrochloride
P AC K AG E L E AF L E T: INFORMAT I ON FO R THE USER Siofor 500 500 mg, film-coated tablet Active substance: metformin hydrochloride For use in children above 10 years and adults Read all of this leaflet
More informationInsulin Pump Therapy
CHILDREN S SERVICES Insulin Pump Therapy These guidelines are not intended for starting a patient on an insulin pump. They are intended to give staff not part of the diabetic team information regarding
More informationHumalog NPL is indicated for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.
HUMALOG NPL 1. NAME OF THE MEDICINAL PRODUCT Humalog NPL 100 U/ml Pen, suspension for injection Humalog NPL 100 U/ml suspension for injection in cartridge 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One
More informationMEDICATION GUIDE WELLBUTRIN (WELL byu-trin) (bupropion hydrochloride) Tablets
MEDICATION GUIDE WELLBUTRIN (WELL byu-trin) (bupropion hydrochloride) Tablets Read this Medication Guide carefully before you start using WELLBUTRIN and each time you get a refill. There may be new information.
More informationBiologic Treatments for Rheumatoid Arthritis
Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been
More informationHuman Normal Immunoglobulin Solution for Intravenous Infusion.
CONSUMER MEDICINE INFORMATION (CMI) OCTAGAM Human Normal Immunoglobulin Solution for Intravenous Infusion. OCTAGAM is available in single use bottles of 20 ml, 50 ml, 100 ml and 200 ml. OCTAGAM contains
More informationThe Family Library. Understanding Diabetes
The Family Library Understanding Diabetes What is Diabetes? Diabetes is caused when the body has a problem in making or using insulin. Insulin is a hormone secreted by the pancreas and is needed for the
More informationDiabetes Subcommittee of PTAC meeting. held 18 June 2008. (minutes for web publishing)
Diabetes Subcommittee of PTAC meeting held 18 June 2008 (minutes for web publishing) Diabetes Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics
More informationDepartment of Health Commencing insulin therapy
Department of Health Commencing insulin therapy Great state. Great opportunity. State of Queensland (Queensland Health) 2008 2013 This work is licensed under a Creative Commons Attribution No Derivatives
More informationType 2 Diabetes: When to Initiate And Intensify Insulin Therapy. Julie Bate on behalf of: Dr John Wilson Endocrinologist Capital and Coast DHB
Type 2 Diabetes: When to Initiate And Intensify Insulin Therapy Julie Bate on behalf of: Dr John Wilson Endocrinologist Capital and Coast DHB Declarations I have received travel funding and speaker fees
More information